{"ticker": {"uuid": "3b7ca13d-2ad6-43a1-be12-782c8017eb29", "symbol": "9966", "name": "Alphamab Oncology", "exchange": "HKG", "country": "HK", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Alphamab Oncology Reports Full Year 2025 Financial Results and Business Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOaklOZ1JDRkl5VUM5OUMtQmdMSjBsdnl1OTlZX3BZNV9Hb3dMbGVDdXBKRHpoY0NKZ1pJU3N3eTN2Zk9ya2ZscnZOZk5VaXBvYVpvOTJjZFpMajFLcjNid0lqc3lTNU5OM1Uya0w0NEhHbzR6UFVmTkFMRHVCQ2xCX0hfblFuRVk2Smh2MlA5czZ0aVhadzNMYlBCaXR4aFpEQWMtSzhGaw?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alphamab Oncology and CSPC\u2019s HER2-Targeting ADC JSKN003 Receives Breakthrough Therapy Designation in China for Advanced Colorectal Cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAJBVV95cUxNTXZZZFFQMnAxTVMyMTB3REtHdy03RHg2bWtsUUVTdExxcDRxcG1nVEtwajRjcjBvS0RBUXZkNnpCQURzSllNZXA1TG8taDZwVWlvTmx5MkR1ZXl4aG5QbFFuNldkOWRTVF8wT2U5WldKdHFJaXdjc0cwM2lWdXNBeGh0V2lBNmJ1dE1IX09RZ0JoS0Y5TWRPOTRnR3ZOcmJjYlNpUG1CTi1DZExVeHZkUkp6Z3B5QzY1aEVwZjJLWXR3Z2JjUGRjcElPYUliWFhqU0Uza1MwbVBpdDcyTWVQWjBCUVljV2h5NUl0NEpxOGU5cEVsYTNBYUgxdnBxZjdSYkd4YkRXblJuR1Nz?oc=5", "source_name": "BioPharma APAC", "published_at": "2025-10-21T07:00:00+00:00", "published_display": "21 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alphamab Oncology\u2019s JSKN003 Gains U.S. FDA Approval for Phase II Study", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQUzhFNllKYXFod1VWTXQzYnRXa202dzNlRHUxMXlyYXBjbk1acnFzUVFoeTRDWEh4VXB1R3A3TGRGRFR4N3RESmlLRzIwZ1VSRHh4d0VSdDFWODgtdDVPZExZUjR1Nzd1aHQwWmIwd0pOSUk3cmFYX0dpTElnWFRHWW1qNzNlVkdBM0l3cXU0c09NODRMaG9pc2JaV3B5a09jbkNKTWlrMnRtZVB4M1hRR3ZmNVNqWThnOXZPMg?oc=5", "source_name": "TipRanks", "published_at": "2025-07-30T07:00:00+00:00", "published_display": "30 Jul 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alphamab Oncology and CSPC\u2019s Anti-HER2 ADC JSKN003 Secures Breakthrough Therapy Designation in China", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxPbjBIS3BLZlhhUXlFY1RSSUt0aldfdlFQZ0FJUWNwNnJYdllCaDg3Q2JkQTlZZTJDcE1TUU92NnV1UUdDbjZBRzZmZ3VFeHRzQnZBeFBLc0tHVVVRZUEyZ2R3SjFabjh2RXdrZkMwbC1HZjdOOVo0X214cXBPeUpwRkt0dWlJUFVodHFKSFRTRFNvTEcycnI2ekRld1ZfNkZDclA4QzJ2YlpNRUZMd1Z3YWlCX1lxdkJ5clFfQmR5WFhhNWEwM1k4OTVJSmFlU2pXU3lrSzlDOERROGM?oc=5", "source_name": "BioPharma APAC", "published_at": "2025-03-19T07:00:00+00:00", "published_display": "19 Mar 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alphamab Oncology Has Received Approval for JSKN033 Clinical Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE5BWTl0ZVA3NVdFYWNDS3FhWURUS0FJWDR2ZWtiMkVueGhYMUhXQ09NWWh6WC1oZklYZmg1VnZrTWJfbVFabnliNjB0ODRHTVo3VkFlQTZHZTdOcUpLcGVLXzcxeHA?oc=5", "source_name": "Oncodaily", "published_at": "2025-01-04T08:00:00+00:00", "published_display": "04 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Firm Advises Underwriters in Alphamab Oncology\u2019s Hong Kong IPO", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNblFCOURSQnpRQlhMN242bjBRVUZqTWttbkpJLU1HR1VCN3VmNFdWdWZiYVhEazUwXzBSLU5RcXNlazBfaWJ1bEc0Wl9ZeXpZdHpFN3pOVjNmM1J5eFIwOWFfaXU3d1pZU2Zsbno0bFdHRnh3dkh3azVkX2RqQzdsZnN0SGdfNm8?oc=5", "source_name": "Latham & Watkins LLP", "published_at": "2019-12-12T08:00:00+00:00", "published_display": "12 Dec 2019 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Alphamab Oncology Reports Full Year 2025 Financial Results and Business Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOaklOZ1JDRkl5VUM5OUMtQmdMSjBsdnl1OTlZX3BZNV9Hb3dMbGVDdXBKRHpoY0NKZ1pJU3N3eTN2Zk9ya2ZscnZOZk5VaXBvYVpvOTJjZFpMajFLcjNid0lqc3lTNU5OM1Uya0w0NEhHbzR6UFVmTkFMRHVCQ2xCX0hfblFuRVk2Smh2MlA5czZ0aVhadzNMYlBCaXR4aFpEQWMtSzhGaw?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alphamab Oncology and CSPC\u2019s HER2-Targeting ADC JSKN003 Receives Breakthrough Therapy Designation in China for Advanced Colorectal Cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAJBVV95cUxNTXZZZFFQMnAxTVMyMTB3REtHdy03RHg2bWtsUUVTdExxcDRxcG1nVEtwajRjcjBvS0RBUXZkNnpCQURzSllNZXA1TG8taDZwVWlvTmx5MkR1ZXl4aG5QbFFuNldkOWRTVF8wT2U5WldKdHFJaXdjc0cwM2lWdXNBeGh0V2lBNmJ1dE1IX09RZ0JoS0Y5TWRPOTRnR3ZOcmJjYlNpUG1CTi1DZExVeHZkUkp6Z3B5QzY1aEVwZjJLWXR3Z2JjUGRjcElPYUliWFhqU0Uza1MwbVBpdDcyTWVQWjBCUVljV2h5NUl0NEpxOGU5cEVsYTNBYUgxdnBxZjdSYkd4YkRXblJuR1Nz?oc=5", "source_name": "BioPharma APAC", "published_at": "2025-10-21T07:00:00+00:00", "published_display": "21 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alphamab Oncology\u2019s JSKN003 Gains U.S. FDA Approval for Phase II Study", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQUzhFNllKYXFod1VWTXQzYnRXa202dzNlRHUxMXlyYXBjbk1acnFzUVFoeTRDWEh4VXB1R3A3TGRGRFR4N3RESmlLRzIwZ1VSRHh4d0VSdDFWODgtdDVPZExZUjR1Nzd1aHQwWmIwd0pOSUk3cmFYX0dpTElnWFRHWW1qNzNlVkdBM0l3cXU0c09NODRMaG9pc2JaV3B5a09jbkNKTWlrMnRtZVB4M1hRR3ZmNVNqWThnOXZPMg?oc=5", "source_name": "TipRanks", "published_at": "2025-07-30T07:00:00+00:00", "published_display": "30 Jul 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alphamab Oncology and CSPC\u2019s Anti-HER2 ADC JSKN003 Secures Breakthrough Therapy Designation in China", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxPbjBIS3BLZlhhUXlFY1RSSUt0aldfdlFQZ0FJUWNwNnJYdllCaDg3Q2JkQTlZZTJDcE1TUU92NnV1UUdDbjZBRzZmZ3VFeHRzQnZBeFBLc0tHVVVRZUEyZ2R3SjFabjh2RXdrZkMwbC1HZjdOOVo0X214cXBPeUpwRkt0dWlJUFVodHFKSFRTRFNvTEcycnI2ekRld1ZfNkZDclA4QzJ2YlpNRUZMd1Z3YWlCX1lxdkJ5clFfQmR5WFhhNWEwM1k4OTVJSmFlU2pXU3lrSzlDOERROGM?oc=5", "source_name": "BioPharma APAC", "published_at": "2025-03-19T07:00:00+00:00", "published_display": "19 Mar 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alphamab Oncology Has Received Approval for JSKN033 Clinical Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE5BWTl0ZVA3NVdFYWNDS3FhWURUS0FJWDR2ZWtiMkVueGhYMUhXQ09NWWh6WC1oZklYZmg1VnZrTWJfbVFabnliNjB0ODRHTVo3VkFlQTZHZTdOcUpLcGVLXzcxeHA?oc=5", "source_name": "Oncodaily", "published_at": "2025-01-04T08:00:00+00:00", "published_display": "04 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Firm Advises Underwriters in Alphamab Oncology\u2019s Hong Kong IPO", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNblFCOURSQnpRQlhMN242bjBRVUZqTWttbkpJLU1HR1VCN3VmNFdWdWZiYVhEazUwXzBSLU5RcXNlazBfaWJ1bEc0Wl9ZeXpZdHpFN3pOVjNmM1J5eFIwOWFfaXU3d1pZU2Zsbno0bFdHRnh3dkh3azVkX2RqQzdsZnN0SGdfNm8?oc=5", "source_name": "Latham & Watkins LLP", "published_at": "2019-12-12T08:00:00+00:00", "published_display": "12 Dec 2019 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 65, "total_relevant": 6, "sentiment_summary": {"positive": 1, "negative": 0, "neutral": 5, "score": 53, "total": 6, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 68, "events": [{"event": "general", "label": "Market update", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "earnings", "label": "Earnings", "weight": 0.55, "count": 1}], "positive_events": 1, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 7.66, "latest_week": "2026-07-10", "one_week_move": 0.4, "four_week_move": 7.9, "twelve_week_move": -35.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.727773, "market_dynamics_buy_signal": false, "relative_strength": -17.075309, "fair_value_gap": 10.2, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 51.9782, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.4% over one week, +7.9% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 47, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "BioPharma APAC", "count": 2}, {"label": "Market source", "count": 1}, {"label": "TipRanks", "count": 1}, {"label": "Oncodaily", "count": 1}, {"label": "Latham & Watkins LLP", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 6}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 3}, {"label": "Regulatory and legal", "count": 2}, {"label": "Earnings", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "68/100 classification confidence."}, {"label": "Company focus", "value": "6", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.4% over one week, +7.9% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Alphamab Oncology Reports Full Year 2025 Financial Results and Business Highlights"}], "updated_at": "2026-07-17T22:23:08.912861+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}